S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Gilead Sciences Hits 6-week Low
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
